Renaissance Technologies
VERA icon

Renaissance Technologies’s Vera Therapeutics VERA Stock Holding History

Renaissance Technologies’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12M Sell
279,528
-177,772
-39% -$6.62M 0.02% 956
2026
Q1 		$18.4M Buy
457,300
+263,900
+136% +$11.4M 0.03% 685
2025
Q4 		$9.79M Buy
+193,400
New +$6.87M 0.02% 925
2025
Q2 		– Sell
-40,600
Closed -$975K – 3930
2025
Q1 		$975K Buy
40,600
+4,900
+14% +$157K ﹤0.01% 2446
2024
Q4 		$1.51M Buy
+35,700
New +$1.58M ﹤0.01% 2231
2024
Q3 		– Sell
-147,800
Closed -$5.35M – 3918
2024
Q2 		$5.35M Buy
147,800
+32,800
+29% +$1.3M 0.01% 1252
2024
Q1 		$4.96M Buy
+115,000
New +$4.1M 0.01% 1411
2023
Q4 		– Sell
-87,200
Closed -$1.2M – 4162
2023
Q3 		$1.2M Buy
+87,200
New +$1.5M ﹤0.01% 2182
2023
Q2 		– Sell
-174,800
Closed -$1.36M – 4287
2023
Q1 		$1.36M Buy
174,800
+149,900
+602% +$1.16M ﹤0.01% 2264
2022
Q4 		$482K Buy
+24,900
New +$451K ﹤0.01% 2968

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies's VERA Position: Q2 2026 in Review

Renaissance Technologies reduced its Vera Therapeutics (VERA) stake by 39% in Q2 2026, selling an estimated $6.62M and leaving 279,528 shares worth $12M. The position accounts for 0.02% of the portfolio, ranked #956.

Renaissance Technologies first reported a position in VERA in Q4 2022 and has held it in 10 quarters since. The position peaked at $18.4M in Q1 2026. 220 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Renaissance Technologies held 279,528 shares of Vera Therapeutics worth $12M as of Q2 2026.
  • Renaissance Technologies sold 177,772 Vera Therapeutics shares in Q2 2026, an estimated $6.62M.
  • Vera Therapeutics made up 0.02% of Renaissance Technologies's portfolio in Q2 2026, its #956 holding.
  • Renaissance Technologies first reported a position in Vera Therapeutics in Q4 2022 and has held it in 10 quarters since.
  • Renaissance Technologies's Vera Therapeutics position peaked at $18.4M in Q1 2026.
  • 220 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.